Frontiers in Medical Science Research, 2023, 5(6); doi: 10.25236/FMSR.2023.050606.
Zhang Yirong1, Guan Mengyun2, Shen Changyin2, Mei Li1
1Liupanshui People's Hospital, Liupanshui, Guizhou, 553000, China
2Zunyi Medical University, Zunyi, Guizhou, 563000, China
Non-left main coronary artery disease is a common coronary artery disease, and about 1/5 patients need percutaneous coronary intervention (PCI). This article reviews the advantages, safety and limitations of using bioabsorbable stents in clinical treatment of non-left main coronary artery disease.
bioabsorbable scaffold (BRS)
Zhang Yirong, Guan Mengyun, Shen Changyin, Mei Li. Clinical application value of bioabsorbable stent in percutaneous coronary intervention for non-left main lesion. Frontiers in Medical Science Research (2023) Vol. 5, Issue 6: 34-37. https://doi.org/10.25236/FMSR.2023.050606.
[1] Cui Zhanqian, Zhao Guowei, Guo Xinjun (2022). Changes of high-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 levels in patients with coronary heart disease implanted with bioabsorbable stents [J]. China Medicine, vol. 17, no. 10, pp. 1455-1458.
[2] Fu Junhui, Huang Jing, Xu Rui, et al(2022). Preparation and biocompatibility of absorbable antibacterial biliary stent [J]. Journal of Ningbo University (Science and Technology Edition), vol. 35, no. 06, pp. 54-62.
[3] Zhu Yongxiang, Cai Jinzan, Zhu Hao, et al(2018). Possible factors and management of early stent thrombosis after bioabsorbable stent implantation [J]. China Journal of Circulation, vol. 33, no. 03, pp. 296-298.
[4] Gao Xun, Ding Song, He Ben, et al(2017). Application status of bioabsorbable stent in percutaneous coronary intervention [J]. China Journal of Interventional Cardiology, vol. 25, no. 03, pp. 163-165.
[5] Wang Yeping, Wang Yueqin, Liu Wenbin, et al(2022). Comparative study of bioabsorbable stent and drug-eluting stent in the treatment of coronary arteriopathy [J]. Journal of Southeast University (Medical Edition), vol. 41, no. 01, pp. 26-34.
[6] Wu Yizhe, Yin Jiasheng, Ge Lei, et al(2020). Clinical results of a 4-year randomized controlled study on the treatment of in situ coronary artery stenosis with XINSORB bioabsorbable sirolimus eluting stent [J]. China Journal of Interventional Cardiology, vol. 28, no. 09, pp. 493-499.
[7] Liang Yubo, Lin Xin, Che Qianqiu, Sun Ruimin, et al(2019). Systematic evaluation of the safety and effectiveness of bioabsorbable stents in percutaneous coronary intervention [J]. China Journal of Evidence-based Cardiovascular Medicine, vol. 11, no. 02, pp. 148-154.
[8] Li Chongjian, Xu Bo, Song Lei, et al (2021). Safety and feasibility of the first use of the bioabsorbable scaffold Firesorb in human body for the treatment of coronary heart disease: results of four-year clinical follow-up [J]. Chinese journal of cardiology, vol. 49, no. 02, pp. 128-135.
[9] Ke Junsong, Yang Wenxue, Zhang Hongyu, et al(2021). Meta-analysis of the safety and effectiveness of bioabsorbable stents and drug-eluting stents in the treatment of acute myocardial infarction [J]. China Journal of Interventional Cardiology, vol. 29, no. 01, pp. 35-43.
[10] Han Zongmao, Gao Jie, Gao Chuanyu, et al(2021). The long-term prognosis of patients with coronary heart disease after percutaneous coronary intervention [J]. Chinese Journal of Practical Diagnosis and Treatment, vol. 35, no. 01, pp. 19-22.